Veracyte 경영진
경영진 기준 점검 4/4
Veracyte CEO는 Marc Stapley, Jun2021 에 임명되었습니다 의 임기는 4.92 년입니다. 총 연간 보상은 $7.42M, 9.4% 급여 및 90.6% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $6.50M 가치에 해당하는 회사 주식의 0.18% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 3.7 년과 5.2 년입니다.
핵심 정보
Marc Stapley
최고경영자
US$7.4m
총 보수
| CEO 급여 비율 | 9.43% |
| CEO 재임 기간 | 4.9yrs |
| CEO 지분 보유율 | 0.2% |
| 경영진 평균 재임 기간 | 3.7yrs |
| 이사회 평균 재임 기간 | 5.2yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • May 20
VCYT: Mixed Price Revisions Will Pressure Expectations For Future Cash Flow Repricing
Narrative Update Veracyte's updated analyst price target shifts to $37.23 from $38.59, as analysts factor in a slightly higher discount rate, more moderate revenue growth expectations, a higher projected profit margin, and a lower assumed future P/E multiple, informed by recent mixed target revisions and a new bullish initiation. Analyst Commentary Recent research on Veracyte reflects a split view, with some firms turning more constructive while several bearish analysts have trimmed price targets and highlighted execution and valuation risks.분석 기사 • May 14
Shareholders Will Be Pleased With The Quality of Veracyte's (NASDAQ:VCYT) Earnings
When companies post strong earnings, the stock generally performs well, just like Veracyte, Inc.'s ( NASDAQ:VCYT...
내러티브 업데이트 • Apr 28
VCYT: Revised Street Views Will Highlight Medium Term Revenue Guidance Story
Analysts now see a modestly lower upside for Veracyte, trimming the consensus price target by a few dollars to around the mid $30s. Recent research reflects a balance between reduced targets from several firms and a newer bullish initiation that emphasizes the company's longer term growth potential.내러티브 업데이트 • Apr 14
VCYT: Bullish Coverage And Margin Reset Will Strengthen Prostate Cancer Risk Position
Analysts now see Veracyte's fair value at $53, up from $51. This revision reflects updated assumptions around growth, profitability and valuation multiples informed by recent Street research, including both fresh coverage and revised price targets.
내러티브 업데이트 • Mar 31
VCYT: Refreshed Models And 2026 Earnings Focus Will Support Long-Term Upside
Analysts have trimmed their average price target on Veracyte by about $1.60 to $47.00, reflecting refreshed models after recent results and updated views on revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent research updates have focused on resetting expectations for Veracyte, with price targets adjusted downward and models refreshed after Q4 results.내러티브 업데이트 • Mar 17
VCYT: NCCN Risk Stratification Focus Will Support Future Cash Flow Repricing
Analysts have lowered their price target on Veracyte from $43.00 to about $38.59, citing updated assumptions for revenue growth, profit margins and future P/E following recent model revisions. This includes a reduced $37 target from one large Wall Street firm after Q4 results.내러티브 업데이트 • Mar 02
VCYT: 2026 Revenue Outlook And Higher Future P/E Will Lift Long-Term Upside
Analysts now set their Veracyte price target at $48.60, compared with $47.50 previously. This reflects updated views on revenue growth, profit margin assumptions and a higher future P/E multiple.내러티브 업데이트 • Feb 16
VCYT: Guideline Support And Margin Reset Will Strengthen Prostate Cancer Risk Role
Analysts have kept their $51.00 price target for Veracyte unchanged, citing updated assumptions that reflect slightly lower discount rates, modestly higher revenue growth expectations, a reduced profit margin outlook, and a higher future P/E multiple. What's in the News Veracyte issued earnings guidance for the fourth quarter of 2025, with expected total revenue between US$138 million and US$140 million, described as 16% to 18% growth for the period.내러티브 업데이트 • Feb 02
VCYT: NCCN Risk Stratification Focus Will Support Future Genomic Test Adoption
Narrative Update on Veracyte Analysts have kept their Veracyte fair value target steady at $43.00, citing updated NCCN prostate cancer guidelines that highlight Decipher’s role in risk stratification and support slightly adjusted assumptions for revenue growth, profit margins, and future P/E. Analyst Commentary Recent commentary points to the updated NCCN prostate cancer guidelines as a supportive data point for Veracyte’s Decipher test.내러티브 업데이트 • Jan 19
VCYT: NCCN Guideline Support Will Strengthen Prostate Cancer Risk Stratification Role
Analysts have lifted their price target on Veracyte from US$45.00 to US$51.00, citing updated NCCN guidelines that they view as incrementally favorable for the company’s Decipher prostate cancer test and its differentiation based on clinical evidence. Analyst Commentary Bullish analysts are framing the latest NCCN prostate cancer guideline update as a meaningful support for Veracyte’s Decipher test, especially around how it is positioned within risk stratification.Seeking Alpha • Jan 16
Veracyte: Profitable, De-Risked, And Ready To Run
Summary Veracyte (VCYT) has transitioned to a profitable, diversified model with strong operating leverage and self-fortifying balance sheet. Key 2025-2026 catalysts include deeper prostate cancer penetration, entry into minimal residual disease, and U.S. re-launch of the Prosigna breast cancer test. VCYT projects 16% revenue growth to $515–$517M in FY25 and >25% adjusted EBITDA margin, signaling sustained profitable execution. A robust digital pathology database and AI-driven bioinformatics platform create significant competitive moats and future product opportunities. Read the full article on Seeking Alpha내러티브 업데이트 • Jan 05
VCYT: NCCN Guideline Support Will Shape Future Decipher Adoption And Competitive Risks
Analysts have lifted their price target on Veracyte from $28.40 to $43.00, citing updated NCCN prostate cancer guidelines that highlight the Decipher test in key risk stratification tables as support for a higher fair value assumption. Analyst Commentary Analysts point to the updated NCCN V3.2026 prostate cancer guidelines as a supportive data point for Veracyte, highlighting that Decipher is explicitly listed in the principles of risk stratification tables across several key prostate cancer settings.내러티브 업데이트 • Dec 15
VCYT: Updated NCCN Guidelines Will Support Gradual Risk Stratification Adoption
Analysts have modestly raised their price target on Veracyte to approximately $47.50 from about $46.30, citing slightly stronger long term growth and profitability expectations, as well as the incremental boost from updated NCCN guidelines that further differentiate the company’s Decipher prostate cancer test. Analyst Commentary Street research characterizes the NCCN guideline update as a net positive for Veracyte, with the Decipher prostate cancer test receiving prominent placement in risk stratification tables across multiple disease stages.내러티브 업데이트 • Nov 29
VCYT: New NCCN Guidelines Will Support Continued Market Differentiation
Analysts have raised their price target for Veracyte from $45.30 to $46.30, citing ongoing positive inclusion of the company’s Decipher test in updated clinical guidelines as a contributing factor. Analyst Commentary Analysts have examined the recent updates to the clinical guidelines and their implications for Veracyte’s Decipher test, highlighting both opportunities and potential challenges facing the company.분석 기사 • Nov 22
Veracyte, Inc. (NASDAQ:VCYT) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Despite an already strong run, Veracyte, Inc. ( NASDAQ:VCYT ) shares have been powering on, with a gain of 27% in the...내러티브 업데이트 • Nov 15
VCYT: Expanded Prostate Cancer Guidelines Will Drive Demand Ahead
Veracyte's analyst price target has been raised from $41.10 to $45.30. Analysts cite stronger guidelines support, as well as improved revenue and profit growth expectations, as key drivers.내러티브 업데이트 • Nov 01
VCYT: Continued Pipeline Success Will Drive Broader Health Market Expansion
Narrative Update: Veracyte Analyst Price Target Revision Analysts have slightly reduced their price target for Veracyte, lowering it by $1 to $28. They cite solid recent performance but note that larger upside may be realized further into the future.내러티브 업데이트 • Oct 18
Advanced Genomic And Cancer Diagnostics Will Expand Global Health Markets
Analysts have modestly raised Veracyte’s fair value estimate to $41.22 from $39.75. They cite continued product momentum and optimistic guidance, despite lingering longer-term uncertainties.분석 기사 • Aug 30
Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Veracyte, Inc. ( NASDAQ:VCYT ) shareholders would be excited to see that the share price has had a great month, posting...분석 기사 • Jun 15
Veracyte, Inc.'s (NASDAQ:VCYT) Shares Lagging The Industry But So Is The Business
You may think that with a price-to-sales (or "P/S") ratio of 4.5x Veracyte, Inc. ( NASDAQ:VCYT ) is a stock worth...분석 기사 • May 10
Veracyte, Inc. Just Beat EPS By 260%: Here's What Analysts Think Will Happen Next
As you might know, Veracyte, Inc. ( NASDAQ:VCYT ) just kicked off its latest quarterly results with some very strong...새로운 내러티브 • May 07
Decipher, Afirma And MRD Tests Will Broaden Future Markets
Veracyte’s Decipher test expansion and updated NCCN guidelines could drive significant revenue growth and market share in the prostate cancer segment.분석 기사 • Mar 08
Shareholders Can Be Confident That Veracyte's (NASDAQ:VCYT) Earnings Are High Quality
Even though Veracyte, Inc. ( NASDAQ:VCYT ) posted strong earnings, investors appeared to be underwhelmed. We have done...분석 기사 • Mar 04
Veracyte, Inc. (NASDAQ:VCYT) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Veracyte, Inc. ( NASDAQ:VCYT ) shareholders that were waiting for something to happen have been dealt a blow with a 26...분석 기사 • Jan 09
Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 50% Above Its Share Price
Key Insights Veracyte's estimated fair value is US$65.48 based on 2 Stage Free Cash Flow to Equity Veracyte is...Seeking Alpha • Dec 11
Veracyte: Getting Frothy
Summary Veracyte has seen its stock more than double since early August, driven by strong Q3 results and increased revenue guidance for FY2024. This medical diagnostic firm focused on oncology is executing well, but the stock looks a bit 'frothy' based on some valuation metrics. The analyst community is also somewhat mixed based on the stock's valuation, and there was some notable insider selling following Q3 results. Can the rally continue in Veracyte? An analysis follows in the paragraphs below. Read the full article on Seeking Alpha분석 기사 • Dec 01
Veracyte, Inc. (NASDAQ:VCYT) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Veracyte, Inc. ( NASDAQ:VCYT ) shares have continued their recent momentum with a 25% gain in the last month alone. The...분석 기사 • Aug 18
Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 42%
Veracyte, Inc. ( NASDAQ:VCYT ) shareholders have had their patience rewarded with a 42% share price jump in the last...분석 기사 • Aug 09
Veracyte, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Shareholders will be ecstatic, with their stake up 39% over the past week following Veracyte, Inc. 's ( NASDAQ:VCYT...분석 기사 • Jul 02
Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 76% Above Its Share Price
Key Insights The projected fair value for Veracyte is US$37.52 based on 2 Stage Free Cash Flow to Equity Veracyte's...분석 기사 • Jun 06
Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking
Veracyte, Inc.'s ( NASDAQ:VCYT ) price-to-sales (or "P/S") ratio of 4.4x might make it look like a strong buy right now...분석 기사 • May 09
Veracyte, Inc. (NASDAQ:VCYT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Veracyte, Inc. ( NASDAQ:VCYT ) investors will be delighted, with the company turning in some strong numbers with its...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$88m |
| Dec 31 2025 | US$7m | US$700k | US$66m |
| Sep 30 2025 | n/a | n/a | US$30m |
| Jun 30 2025 | n/a | n/a | US$26m |
| Mar 31 2025 | n/a | n/a | US$33m |
| Dec 31 2024 | US$7m | US$675k | US$24m |
| Sep 30 2024 | n/a | n/a | -US$9m |
| Jun 30 2024 | n/a | n/a | -US$54m |
| Mar 31 2024 | n/a | n/a | -US$68m |
| Dec 31 2023 | US$7m | US$650k | -US$74m |
| Sep 30 2023 | n/a | n/a | -US$50m |
| Jun 30 2023 | n/a | n/a | -US$29m |
| Mar 31 2023 | n/a | n/a | -US$30m |
| Dec 31 2022 | US$5m | US$625k | -US$37m |
| Sep 30 2022 | n/a | n/a | -US$43m |
| Jun 30 2022 | n/a | n/a | -US$49m |
| Mar 31 2022 | n/a | n/a | -US$48m |
| Dec 31 2021 | US$6m | US$350k | -US$76m |
보상 대 시장: Marc의 총 보수(USD7.42M)는 US 시장에서 비슷한 규모 기업의 평균(USD7.03M) 수준입니다.
보상과 수익: Marc의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Marc Stapley (55 yo)
4.9yrs
재임 기간
US$7,421,877
보수
Mr. Marc A. Stapley serves as Chief Executive Officer at Veracyte, Inc. since June 1, 2021 and serves as its Director since June 08, 2021. He served as the Chief Executive Officer of Helix OpCo, LLC from A...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Director | 4.9yrs | US$7.42m | 0.18% $ 6.5m | |
| Executive VP & CFO | 4.8yrs | US$2.88m | 0.045% $ 1.6m | |
| Chief Scientific & Medical Officer | 2.6yrs | US$2.50m | 0.040% $ 1.4m | |
| Executive VP | 4.3yrs | US$2.79m | 0.0014% $ 51.2k | |
| Global Chief Commercial Officer | 3.7yrs | US$3.20m | 0.023% $ 830.4k | |
| Senior Vice President of Global Operations | 1.5yrs | 데이터 없음 | 데이터 없음 | |
| VP & Chief Accounting Officer | 4.3yrs | 데이터 없음 | 0.0099% $ 355.5k | |
| Chief Development and Technology Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Senior VP & Chief Information Officer | 4.3yrs | 데이터 없음 | 데이터 없음 | |
| Director of Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Corporate Marketing | 2.3yrs | 데이터 없음 | 데이터 없음 | |
| Chief Human Resources Officer | less than a year | 데이터 없음 | 데이터 없음 |
3.7yrs
평균 재임 기간
53yo
평균 나이
경험이 풍부한 관리: VCYT의 경영진은 경험이 있음으로 간주됩니다(평균 재임 3.7 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Director | 4.9yrs | US$7.42m | 0.18% $ 6.5m | |
| Independent Director | 13.4yrs | US$324.99k | 0.0053% $ 191.5k | |
| Independent Director | 18.3yrs | US$324.99k | 0.025% $ 905.8k | |
| Independent Chair | 11.3yrs | US$359.99k | 0.067% $ 2.4m | |
| Independent Director | 5.8yrs | US$327.49k | 0.022% $ 808.1k | |
| Independent Director | 1.7yrs | US$307.49k | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 5.2yrs | US$309.99k | 0.038% $ 1.4m | |
| Independent Director | 1.7yrs | US$304.99k | 데이터 없음 | |
| Independent Director | 3.8yrs | US$304.99k | 0.044% $ 1.6m |
5.2yrs
평균 재임 기간
62yo
평균 나이
경험이 풍부한 이사회: VCYT의 이사회는 경험이 있음으로 간주됩니다(평균 재임 5.2 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/21 08:42 |
| 종가 | 2026/05/21 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Veracyte, Inc.는 24명의 분석가가 다루고 있습니다. 이 중 11명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Sung Ji Nam | BTIG |
| Kyle Mikson | Canaccord Genuity |